This is an open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in subjects with persistent or recurrent endometrial carcinoma.
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.